LUMIMIND PSYCHIATRY & WELLNESS Announces Use of Objective ADHD Testing Technology for Diagnosis and Treatment

Test Aims to Give Providers Increased Clinical Confidence Through Objective

Data

Miami, FL, MAY 28th, 2025 – LUMIMIND PSYCHIATRY & WELLNESS today announces its adoption of QbTest, an objective ADHD test providing clinicians with actionable data for unbiased decision-making and support. The test, created by the global leader in ADHD testing, Qbtech, is the first FDA-cleared solution to aid clinicians when diagnosing and treating ADHD in children, adolescents, and adults.

Qbtech offers both in-clinic and telehealth testing capabilities, which are conducted with a healthcare provider. Using a medical device administered on a computer, the in-clinic assessment uses an infrared tracking camera and head sensor to measure core ADHD symptoms – activity, inattention, and impulsivity – through a 15-20-minute computer-based test. Results are instantly analysed and presented in a report that compares a patient’s results with a group of people of the same age and sex at birth without ADHD.

J.D quoted “We are excited to onboard a revolutionary technology to help our clinicians better understand core ADHD symptoms,” says JD. “QbTest provides an opportunity to improve our care model for patients struggling with ADHD by providing objective, tangible results for a more comprehensive ADHD evaluation and treatment management program.”

The data from QbTest can be utilized to enable clinicians to determine treatment effects more accurately and efficiently. This provides patients with access to tailored treatment more quickly, an outcome that can improve the quality of life for patients.

“Qbtech prides itself on providing our clinicians with industry-leading technology to treat their patients,” said Tony Doyle, Commercial Director at Qbtech. “ADHD has a significant role in the current mental health crisis, and incorporating objective data into the standard treatment of care is critical for patients to be treated effectively and efficiently.”

LUMIMIND PSYCHIATRY & WELLNESS joins the growing list of nearly 10,000 clinicians globally adopting objective measures to more accurately rule in or rule out ADHD for their patients. Qbtech has administered more than 600,000 tests, 120,000 conducted via telehealth.

The test will be offered at LUMIMIND PSYCHIATRY & WELLNESS, VIA TELEHEALTH starting MAY 22ND, 2025 and implemented for all patients struggling with ADHD. For more information visit www.qbtech.com.

​

About Qbtech

Founded in 2002, Qbtech is a privately owned Swedish company that has developed leading solutions and products for improving the diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS’. www.qbtech.com

​

LumiMind Psychiatry & Wellness, founded by board-certified Psychiatric Mental Health Nurse Practitioner Belkis B. Perez, PMHNP-BC, AGPCNP, AGACNP-BC, is a premier psychiatric clinic specializing in evidence-based care for ADHD, depression, anxiety, and PTSD. Leveraging advanced tools like the FDA-cleared QbTest and accessible telepsychiatry, LumiMind delivers personalized diagnostics and treatments, including pharmacotherapy, CBT, and mindfulness, to empower patients. With a commitment to precision, accessibility, and holistic care, LumiMind partners with clinicians to enhance mental health outcomes.